Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 positive |
Therapy | Atezolizumab + Tiragolumab |
Indication/Tumor Type | lung non-small cell carcinoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | lung non-small cell carcinoma | predicted - sensitive | Atezolizumab + Tiragolumab | Phase II | Actionable | In a Phase II trial (CITYSCAPE), Tiragolumab (MTIG7192A) and Tecentriq (atezolizumab) combination therapy as first-line treatment improved objective response rate (37.3%, 25/67 vs 20.6%, 14/68) and median progression-free survival (5.6 vs 3.9 mo) compared to Tecentriq (atezolizumab) plus placebo in patients with CD274 (PD-L1)-positive (TPS>=1%) advanced or metastatic non-small cell lung cancer (J Clin Oncol 38, no. 15_suppl (May 20, 2020) 9503-9503; NCT03563716). | detail... |
CD274 positive | lung non-small cell carcinoma | predicted - sensitive | Atezolizumab + Tiragolumab | Phase I | Actionable | In a Phase Ia/Ib trial (GO30103), treatment with the combination of Tecentriq (atezolizumab) and Tiragolumab (MTIG7192A) demonstrated safety and efficacy in patients with CD274 (PD-L1)-positive (>/=1%) immunotherapy-naive metastatic non-small cell lung cancer, resulting in an objective response rate of 46% (6/13, 2 complete and 4 partial responses), a disease control rate of 77% (10/13), and a duration of response of 24.2 months (PMID: 37768658; NCT02794571). | 37768658 |
PubMed Id | Reference Title | Details |
---|---|---|
Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE). | Full reference... | |
(37768658) | Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors: A Phase 1a/1b Nonrandomized Controlled Trial. | Full reference... |